A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models

PURPOSE: The clinical application of gemcitabine (GEM) is limited by its pharmacokinetic properties. The aim of this study was to characterize the stability in circulating plasma, tumor targeting, and payload release of liposome-encapsulated GEM, FF-10832. METHODS: Antitumor activity was assessed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Takeshi, Komori, Takashi, Yoshino, Yuta, Ioroi, Tadaaki, Kitahashi, Tsukasa, Kitahara, Hiromu, Ono, Kohei, Higuchi, Tamami, Sakabe, Masayo, Kori, Hiroshi, Kano, Masahiro, Hori, Ritsuko, Kato, Yukio, Hagiwara, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217058/
https://www.ncbi.nlm.nih.gov/pubmed/33961188
http://dx.doi.org/10.1007/s11095-021-03045-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217058/
https://www.ncbi.nlm.nih.gov/pubmed/33961188
http://dx.doi.org/10.1007/s11095-021-03045-5

Ejemplares similares